The 2 most recent market catalysts affecting $TBPH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 55
BTIG Suspends Neutral Rating on Theravance Biopharma
BTIG has suspended its Neutral rating on Theravance Biopharma. This action indicates that the analyst firm is likely undertaking a review of its investment thesis for TBPH, which c…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 92
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate
Theravance Biopharma (TBPH) announced Q2 earnings where adjusted EPS dramatically exceeded expectations, turning a loss from the prior year into a profit. This strong EPS performan…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.